For instance, our group has extensively tested Liraglutide (LIRA) in an established loss-of-function rat model of WS (Wfs1 coding exon 5 knock-out, Wfs1KO) to show that treatment can substantially delay the onset of glucose intolerance and loss of vision (16–18). This evidence concerns the gene WFS1 and Werner syndrome.